Literature DB >> 26848023

Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.

Debasish Basak1, Surendra R Punganuru1, Kalkunte S Srivenugopal1.   

Abstract

Piperlongumine (PL), a small molecule alkaloid present in black pepper (Piper longum), has been reported to kill tumor cells irrespective of their p53 gene status, however, the mechanisms involved are unknown. Since p53 is a redox-sensitive protein, we hypothesized that the redox imbalance induced by PL may affect the structure and/or function of the mutant p53 protein and promote cell death. We used two human colon cancer cell lines, the HT29 and SW620 which harbor the R273H DNA contact abrogatory mutation in p53. PL treatment induced significant ROS production and protein glutathionylation with a concomitant increase in Nrf-2 expression in both cell lines. Surprisingly, immunoprecipitation with wt-p53 specific antibodies (PAb1620) or direct western blotting showed a progressive generation of wild-type-like p53 protein along with a loss of its mutant counterpart in PL-treated HT29 and SW620 cells. Moreover, the EMSA and DNA-affinity blotting revealed a time-dependent restoration of DNA-binding for the mutant p53, which was accompanied by the induction of p53 target genes, MDM2 and Bax. PL, while cytotoxic by itself, also increased the cell killing by many anticancer drugs. In nude mice bearing the HT29 tumors, PL alone (7.5 mg/kg daily) produced a 40% decrease in tumor volume, which was accompanied by diminished intratumoral mutant p53 protein levels. The antitumor efficacy of BCNU or doxorubicin in HT29 xenografts was highly potentiated by PL, followed by expression of apoptotic proteins. These clinically-relevant findings suggest that PL-induced oxidative milieu facilitates a weak functional restoration of mutant p53 through protein glutathionylation and contributes to the increased drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26848023     DOI: 10.3892/ijo.2016.3372

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models.

Authors:  Jiyan Mohammad; Harsharan Dhillon; Shireen Chikara; Sujan Mamidi; Avinash Sreedasyam; Kishore Chittem; Megan Orr; John C Wilkinson; Katie M Reindl
Journal:  Oncotarget       Date:  2017-12-23

2.  The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct.

Authors:  Liangyuan Long; Xiangnan Hu; Xiaoli Li; Duanfang Zhou; Yun Shi; Lingen Wang; Hongfang Zeng; Xiaoping Yu; Weiying Zhou
Journal:  Onco Targets Ther       Date:  2020-05-04       Impact factor: 4.147

Review 3.  The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC).

Authors:  Debasish Basak; Mohammad Nasir Uddin; Jake Hancock
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

Review 4.  More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Authors:  Paulina Pecyna; Joanna Wargula; Marek Murias; Malgorzata Kucinska
Journal:  Biomolecules       Date:  2020-07-27

5.  Piperlongumine Attenuates High Calcium/Phosphate-Induced Arterial Calcification by Preserving P53/PTEN Signaling.

Authors:  Wenxiang Shi; Jieyu Lu; Junhan Li; Ming Qiu; Yan Lu; Jia Gu; Xiangqing Kong; Wei Sun
Journal:  Front Cardiovasc Med       Date:  2021-02-10

Review 6.  The promising potential of piperlongumine as an emerging therapeutics for cancer.

Authors:  Dey Parama; Varsha Rana; Sosmitha Girisa; Elika Verma; Uzini Devi Daimary; Krishan Kumar Thakur; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30

7.  Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.

Authors:  Wei Hang; Zhi-Xian Yin; Gang Liu; Qinghua Zeng; Xiang-Feng Shen; Qian-Hui Sun; Dong-Dong Li; Yong-Ping Jian; Yang-He Zhang; Yi-Shu Wang; Cheng-Shi Quan; Rui-Xun Zhao; Yu-Lin Li; Zhi-Xiang Xu
Journal:  Oncogene       Date:  2018-01-18       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.